Absstract of: US20260356970A1
The present disclosure provides antibodies, antigen binding fragments thereof, and fusion proteins, including chimeric antigen receptors, that target EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2). Also provided herein are methods of using such antibodies, antigen binding fragments thereof, and fusion proteins, for treating hematopoietic malignancies or hematological diseases (e.g., acute myeloid leukemia, myelodysplastic syndrome).
Absstract of: US20260356950A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a GPRC5DxCD3 bispecific antibody on a monthly dosing schedule.
Absstract of: US20260356912A1
Provided are a chimeric antigen receptor, and a GPRC5D antibody-containing chimeric antigen receptor and use thereof. The chimeric antigen receptor includes: an extracellular domain, capable of binding to a tumor antigen; a transmembrane domain, linked to the extracellular domain, the transmembrane domain being from a type I transmembrane protein or is an artificially synthesized transmembrane protein with a hydrophobic helix; and an intracellular domain, linked to the transmembrane domain. The tumor antigen is a tumor-specific antigen or a tumor-associated antigen. The amino acid sequence of the transmembrane domain is optimized, thereby providing the chimeric antigen receptor containing the GPRC5D antibody and an engineered immune cell. The engineered immune cell obtained based on the GPRC5D antibody exhibits a specific killing activity against multiple myeloma.
Absstract of: US20260356961A1
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
Absstract of: AU2025260405A1
Disclosed herein are 4,6-substituted-2-(3'-1,1'-biphenyl-4-yl)quinoline analogs and pharmaceutically acceptable salts thereof that are inhibitors of dihydroorotate dehydrogenase (DHODH) with properties, including stability and bioavailability as disclosed herein. Also disclosed herein are methods of making the analogs and salts thereof. The disclosed analogs and salts thereof can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation.
Absstract of: WO2026236257A1
Described herein are methods of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma. Also described herein are methods of determining treatment for a subject having multiple myeloma. The methods may comprise detecting a level of HAPLN1 protein in a peripheral blood sample.
Absstract of: US20260355311A1
Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.
Absstract of: WO2026236382A1
The invention provides methods of dosing for the treatment of multiple myeloma, with cevostamab or a combination treatment comprising cevostamab and pomalidomide.
Absstract of: WO2026235637A1
The present invention relates, in general terms, to the field of molecular biology Specifically, the invention relates to nucleic acid inhibitors and their use in treating cancers. In one embodiment, the nucleic acid inhibitor is a steric antisense oligonucleotide (ASO) that is capable of inhibiting the interaction between a NF-KB/p52 regulated long non-coding RNA (IncRNA), LINC02362, and an Enhancer of Zeste Homolog 2 (EZH2) polypeptide. In this specification, the LINC02362 is also termed as PLUM (PRC2 associated LncRNA regulating QPR in MM). The steric ASO may bind to PLUM, which may cause the PLUM-EZH2 interaction to be inhibited, and may further re-sensitize the multiple myeloma (MM) cells to drug treatment or chemotherapy.
Absstract of: WO2026235565A1
Herein disclosed is an engineered human bone-marrow-on-chip platform and multiplex proteomic methods for mapping leukemia– niche signaling and drug resistance. The platform comprises interacting 3D microenvironments mimicking endosteal-like and vascular-like bone marrow niches, optionally integrated within a multi-compartment microfluidic device configured for perfusion and dynamic infusion of leukemia cells and drugs. In preferred embodiments, a porous bone-mimetic scaffold forms the endosteal- like niche and a hydrogel supports spontaneous formation of interconnected vascular networks forming the vascular-like niche. Distinct niche and leukemia cell populations are pre-labeled with different stable-isotope amino acids (e.g., 4-plex SILAC) prior to assembly and co-culture. After leukemia exposure and/or chemotherapy treatment, compartment-resolved recovery of endosteal-attached cells, vascular-located cells, circulating leukemia blasts and secretome enables quantitative mass spectrometry to reconstruct directional signaling networks and identify pathways associated with niche remodeling, stress responses, dormancy and drug resistance. The invention further provides methods, devices and kits for precision drug screening, biomarker discovery and therapy guidance related to minimal residual disease and relapse.
Absstract of: US20260357267A1
The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as β-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
Absstract of: AU2026257525A1
Abstract The present disclosure relates to the use of 1-4-bromo-5-1-ethyl-7-(methylamino)-2-oxo- 1,2-dihydro-1,6-naphthyridin-3-yl-2-fluorophenyl-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo- 1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia- associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma. ct b s t r a c t c t
Absstract of: WO2026234583A1
Antibody molecule targeting Syndecan-1 for use in the treatment of multiple myeloma and plasmacytoma The invention pertains to an anti-CD138 antibody molecule capable of binding CD138. The antibody molecule may be conjugated to a cytotoxic agent to form an antibody-drug conjugate or conjugated to a nanoparticle bearing a therapeutic agent. The disclosure also provides isolated nucleic acid molecules encoding the antibody molecule of the invention, as well as a host cell that expresses the antibody molecule. The antibody molecule is also provided for use as a medicament, for the therapeutic treatment of tumors and for tumor diagnosis, as well as for use in an in vitro method for detecting CD138-expressing cells in a biological sample.
Absstract of: EP4837911A1
Disclosed in the present invention are three crystal forms of thienopyrimidine compound A and a preparation method therefor, wherein crystal form I is of a trihydrochloride salt, and crystal form II and III are of dihydrochloride salts. The three crystal forms all have good stability and solubility, with a solubility of ≥4 mg/mL in a 5% aqueous glucose solution, so that the basic requirements for the solubility of a compound to be prepared into a lyophilized preparation for injection are met. The three crystal forms of thienopyrimidine compound A prepared in the present invention have good stability and solubility, can be prepared into a lyophilized preparation for clinical injection, and can be used for the effective treatment of patients with advanced, recurrent, etc. lymphoma, myeloma and lymphocytic leukemia, or drug-resistant patients.
Absstract of: WO2026229443A1
The invention relates to a composition or a kit comprising a Toll-like receptor agonist and an Interleukin-7 (IL-7) antagonist as well as methods and uses for treating or preventing lymphoblastic leukemia.
Absstract of: WO2026231609A1
Provided herein are methods of treating certain B cell lymphomas comprising administering a T-cell engager (TCE) in combination with 3-(6-(((3R,4R)-1-(5-chloro-4-((1-methyl-2-oxoindolin-5-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-yl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt thereof.
Absstract of: US20260345683A1
0000 The present study of the regulatory T phenotype of Sézary cells led to the discovery of the overexpression of CD81 by Sézary cells. CD81 has also been shown to be a relevant therapeutic target in the treatment of Sézary syndrome, NK/T lymphoma, hepatosplenic T-cell lymphoma and acute T cell leukemia. CD81 therefore appears as a diagnostic marker and as a therapeutic target in T-cell malignancies. Accordingly, the present invention relates CD81 as a biomarker and biotarget in T-cell malignancies.
Absstract of: US20260345618A1
The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, Pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.
Absstract of: US20260347349A1
0000 CXCR4 antagonists and pharmaceutical formulations thereof are disclosed. The compounds and pharmaceutical formulations disclosed herein can be used to antagonize the CXCR4 pathway for mobilizing stem cells or treating a condition, disorder, or disease associated with the CXCR4 pathway. Exemplary conditions, disorders, and diseases relevant to this disclosure include HIV infections, WHIM syndrome, Waldenström macroglobulinemia, chronic neutropenia, primary immune-deficiency, aplastic anemia, hypoplastic myelodysplastic syndrome, acute respiratory distress syndrome (ARDS), ankylosing spondylitis, autoimmune diseases, and cancers.
Absstract of: US20260347354A1
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
Absstract of: US20260345680A1
0000 Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) targeting B-cell maturation antigen (BC-MA) induces high overall response rates. However, relapse occurs frequently and novel strategies for CAR-T cells targeting MM cells are needed. CAR-T cells targeting CD38 represent a potential alternative, but expression of CD38 on activated T cells and other hematopoietic cells raises concerns about the efficacy and safety of such therapy. Here, the inventors developed DCAR, a double CAR system targeting CD38 and SLAMF7 (CS1) through split activation and co-stimulation receptors, respectively. Furthermore, the inventors show that CRISPR/Cas9 inactivation of the CD38 gene enhances the anti-MM activity of DCAR-T in vitro. Edited DCAR-T developed strong responses specifically against MM cells expressing both the CD38 and the CS1 antigens in vitro and in vivo. Importantly, the inventors bring evidence that, unlike anti-CD38 CAR-T, which elicited a severe immune reaction against hematopoietic cells in a humanized mouse model, DCAR-T showed no sign of toxicity. Accordingly, the present invention relates to novel dual split CAR-T cells and uses thereof for the treatment of CD38-positive hematological malignancies.
Absstract of: US20260345647A1
0000 A treatment method, comprising using a drug containing AST-3424, AST-3423 or AST-2870 and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof in combination with a drug containing cytarabine or daunorubicin and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof to treat leukemia and lymphoma patients. Where the concentration of daunorubicin or cytarabine is far lower than the clinical dosage thereof, there is no need to limit patients to those with higher (overexpression, excess) AKR1C3 protein or RNA expression; the combination of AST-3424 and cytarabine or daunorubicin still has a remarkable inhibitory effect on the in-vitro proliferation of leukemia or lymphoma cells, and the combination has a relatively good inhibitory effect on the in-vitro proliferation of cell lines with different levels of AKR1C3 protein or RNA expression. Therefore, the described combination protocol is expected to be developed into a new treatment protocol for treating leukemia and lymphoma without limiting the level of AKR1C3 enzyme expression in patients.
Absstract of: WO2026228549A1
The present invention relates to an antigen-binding molecule that specifically binds to CD38, a conjugate comprising same, and the medical use thereof. Specifically, the present invention relates to an antibody-drug conjugate that specifically binds to CD38 and the use thereof in a drug for treating multiple myeloma.
Absstract of: US20260347948A1
0000 Methods for treating and/or assessing a subject having a symptomatic multiple myeloma or a precursor thereof, where the methods involve characterizing a plasma cell dyscrasia (e.g., monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, multiple myeloma, plasma cell leukemia) in a biological sample from a subject as being high, medium, or low risk by assigning to the plasma cell dyscrasia a multiple myeloma (MM)-like score. The methods may involve sequencing DNA from the biological sample using whole-genome sequencing (WGS).
Nº publicación: US20260350412A1 05/11/2026
Applicant:
CYTEK BIOSCIENCES INC [US]
Cytek Biosciences, Inc.
Absstract of: US20260350412A1
Methods of speeding the training of a convolutional neural network (CNN) to classify new images of biological cells captured by an imaging flow cytometer (IFC) are disclosed. Transfer learning with and without mapping is used based on the selection of pre-trained CNN to be used. New images of biological cells can be classified with new classes that are provided such as classes for red blood cells and classes for DNA damage of lymphoma biological cells.